MintNeuro Advances Semiconductor Strategy and Talent Expansion in Neurotechnology Push

MintNeuro, a London-based deep-tech start-up developing implantable neurotechnology, featured prominently this week as it advanced both its semiconductor strategy and organizational build-out. The company framed the semiconductor layer as critical infrastructure for scalable brain-computer interfaces and closed-loop neurotech systems.

In a State of the Future discussion with Cloudberry VC’s Lawrence Lundy-Bryan, co-founder and CEO Dorian Haci emphasized heterogeneous integration, chiplets, and modular, standardized chip platforms over bespoke hardware. This semiconductor-centric approach is positioned to reduce development costs and time-to-market, while enabling applications in stroke recovery, epilepsy, Parkinson’s, dementia, and severe mental health disorders.

MintNeuro also continued to expand its engineering team in London, recruiting for senior analogue/mixed-signal IC design, software/firmware, junior electronics roles, and several internships. The hiring push underscores a shift from early R&D to more advanced product development, with a focus on ultra-low-power, high-performance silicon for implantable medical devices.

The planned senior IC hire will own key subsystems from architecture through silicon validation and contribute to multiple IC tape-outs, building in-house capability in a specialized neurotechnology niche. This expansion suggests higher R&D intensity and operating expenses, but also the potential creation of defensible intellectual property and stronger competitive positioning if clinical and commercial milestones are achieved.

Thought leadership further elevated MintNeuro’s profile, with Haci outlining the company’s vision for next-generation neural interfaces and neuro-aware systems in Test Labs – Medical Devices’ Outlook magazine. He highlighted how converging advances in neurotechnology, semiconductors, and AI could reshape human-machine interaction, digital healthcare, and treatments for neurological and mental health conditions.

The company also announced Haci as an invited speaker at Hardware Pioneers Max 2026 in London, where he will address the integration of neuroscience, semiconductor technology, and next-generation hardware for brain-computer interfaces. While no funding rounds, revenue figures, or specific commercialization timelines were disclosed, the week’s developments point to deliberate platform-building, ecosystem positioning, and investor engagement.

Taken together, MintNeuro’s focus on semiconductor-centric architectures, talent acquisition, and industry visibility indicates a long-term strategy centered on scalable neurotechnology platforms rather than near-term commercial milestones. The overall week reflected incremental but strategically important progress in technical capability and brand recognition for the company.